查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1606869

促红血球生成素兴奋剂市场：按类型、按应用分类 - 全球预测 2025-2030

Erythropoietin Stimulating Agents Market by Type (Darbepoetin Alfa, Epoetin Alfa, Epoetin Beta), Application (Anemia, Antiretroviral Treatment, Cancer Chemotherapy) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年促红血球生成素兴奋剂市值为98.4亿美元，预计2024年将达到103.2亿美元，复合年增长率为5.64%，预计到2030年将达到144.5亿美元。

促红血球生成素 (ESA) 是一种生物工程药物，用于刺激红血球生成，主要用于因慢性肾臟病、癌症治疗或某些慢性疾病而患有贫血的患者。这些药物，包括阿法依泊汀和Darbepoetin汀，透过减少输血需求在医疗中发挥重要作用。 ESA 的需求和范围扩展到终末期肾病的贫血管理，并且越来越多地在非透析依赖性慢性肾臟病和其他贫血相关疾病中进行研究。市场终端用途多种多样，包括医院、诊所和门诊手术中心。

主要市场统计
基准年[2023] 98.4亿美元
预测年份 [2024] 103.2亿美元
预测年份 [2030] 144.5亿美元
复合年增长率（%） 5.64%

慢性病盛行率上升、人口老化和生技药品需求增加推动了市场成长。此外，对具有更高效率和安全性的仿生促红血球生成素和 ESA 的研究正在进行中，为市场提供了潜在的机会。具有成本效益的生物相似药的开拓也为更广泛的市场进入打开了大门，特别是在新兴经济体。然而，高製造成本、严格的监管途径以及围绕血栓栓塞事件和心血管风险的安全担忧等挑战正在限制市场成长。此外，来自替代疗法的竞争和对患者特异性治疗的需求是进一步的市场限制。

为了利用成长机会，公司应专注于加速长效 ESA 和个人化治疗解决方案的研究。与医疗保健提供者合作进行临床研究并利用人工智慧制定个人化治疗策略可提供策略优势。优化疗效和病人依从性的给药机制创新也是一个有前景的领域。 ESA 市场是一个动态市场，其特点是严格的法律规范和持续的科学探索，这表明公司应优先考虑合规性和适应性创新才能取得成功。随着全球医疗保健系统转向基于价值的护理，确保 ESA 的成本效益和有效性对于市场的可持续性和扩张至关重要。

市场动态：快速发展的促红血球生成素刺激剂市场的关键市场洞察

供需的动态交互作用正在改变促红血球生成素兴奋剂市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球爱滋病毒、癌症和末期肾病 (ESRD) 发病率不断上升
    • 由于重组 DNA 技术的改进，合成 ESRD 的发展加快
    • 政府积极努力扩大医疗基础设施
  • 市场限制因素
    • 高成本EPO药物
  • 市场机会
    • 新药和具有成本效益的生物相似药介绍
    • 创新分子开发的持续研发活动
  • 市场挑战
    • 严格的药品核准监理通讯协定

波特五力：引领促红血球生成素兴奋剂市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解促红血球生成素兴奋剂市场的外部影响

外部宏观环境因素在塑造促红血球生成兴奋剂市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解促红血球生成素兴奋剂市场的竞争格局

对促红血球生成素兴奋剂市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵促红血球生成素刺激器市场供应商的绩效评估

FPNV定位矩阵是评估促红血球生成素兴奋剂市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製促红血球生成素兴奋剂市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对促红血球生成素兴奋剂市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球爱滋病毒、癌症和末期肾功能衰竭的发生率正在上升
      • 透过增强重组 DNA 技术促进 ESRD 合成形式的开发
      • 政府加强医疗基础设施的有利倡议
    • 抑制因素
      • 昂贵的促红血球生成素药物
    • 机会
      • 新药和具有成本效益的生物相似药介绍
      • 持续的研发活动开发创新分子
    • 任务
      • 严格的药品核准监理通讯协定
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章促红血球生成素兴奋剂市场：依类型

  • Darbepoetin汀阿尔法
  • 阿尔法依泊汀
  • β-促红血球生成素
  • 促红血球Delta素δ
  • 依泊汀欧米茄

第七章促红血球生成素兴奋剂市场：依应用分类

  • 贫血
  • 抗逆转滤病毒治疗
  • 癌症化疗
  • 肾臟疾病
  • 神经系统疾病
  • 肿瘤疾病
  • 伤口癒合

第八章美洲促红血球生成素兴奋剂市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区促红血球生成素兴奋剂市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲促红血球生成素兴奋剂市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Amgen Inc.
  • Biocon Limited
  • Celltrion, Inc.
  • Cipla Limited
  • Dr. Reddys Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Intas Pharmaceuticals Limited
  • Johnson & Johnson
  • Kyowa Kirin Co., Ltd.
  • LG Life Sciences Ltd.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-2D6687430059

The Erythropoietin Stimulating Agents Market was valued at USD 9.84 billion in 2023, expected to reach USD 10.32 billion in 2024, and is projected to grow at a CAGR of 5.64%, to USD 14.45 billion by 2030.

Erythropoietin Stimulating Agents (ESAs) are biologically engineered drugs used to promote red blood cell production, mainly for patients suffering from anemia due to chronic kidney disease, cancer treatments, or certain chronic conditions. These agents, including epoetin alfa and darbepoetin alfa, play a critical role in medical therapeutics by reducing the need for blood transfusions. The necessity and application of ESAs extend to the management of anemia in end-stage renal disease and are increasingly being explored in non-dialysis-dependent chronic kidney disease and other anemia-linked conditions. The market's end-use scope spans hospitals, clinics, and ambulatory surgical centers.

KEY MARKET STATISTICS
Base Year [2023] USD 9.84 billion
Estimated Year [2024] USD 10.32 billion
Forecast Year [2030] USD 14.45 billion
CAGR (%) 5.64%

Market growth is driven by the rising prevalence of chronic diseases, an aging population, and an increased demand for biologics. Furthermore, ongoing research into biomimetic erythropoietin and ESAs with improved efficiency and safety profiles presents potential opportunities in the market. The development of cost-effective biosimilars also opens avenues for broader market access, especially in emerging economies. However, challenges such as high production costs, stringent regulatory pathways, and safety concerns surrounding thromboembolic events and cardiovascular risks limit market growth. Additionally, competition from alternative therapies and the need for patient-specific treatments present further market constraints.

To harness growth opportunities, businesses should focus on advancing research into long-acting ESAs and individualized therapy solutions. Collaborations with healthcare providers for clinical research and leveraging artificial intelligence for personalized treatment strategies can provide strategic advantages. Innovating delivery mechanisms to optimize efficacy and patient compliance is also a promising area. The ESA market remains dynamic, characterized by stringent regulatory oversight and ongoing scientific exploration, suggesting that firms should prioritize compliance and adaptive innovation to succeed. As healthcare systems globally push towards value-based care, ensuring the cost-effectiveness and efficacy of ESAs will be crucial for market sustainability and expansion.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Erythropoietin Stimulating Agents Market

The Erythropoietin Stimulating Agents Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidence of HIV, cancer, and ESRD globally
    • Increasing development of synthetic forms of ESRD with enhanced recombinant DNA technology
    • Favorable government initiatives to increase healthcare infrastructures
  • Market Restraints
    • High cost EPO drugs
  • Market Opportunities
    • Introduction of novel drugs and cost-efficient biosimilar formulations
    • Ongoing robust research and development activities to develop innovative molecules
  • Market Challenges
    • Stringent regulatory protocols for drug approval

Porter's Five Forces: A Strategic Tool for Navigating the Erythropoietin Stimulating Agents Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Erythropoietin Stimulating Agents Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Erythropoietin Stimulating Agents Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Erythropoietin Stimulating Agents Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Erythropoietin Stimulating Agents Market

A detailed market share analysis in the Erythropoietin Stimulating Agents Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Erythropoietin Stimulating Agents Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Erythropoietin Stimulating Agents Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Erythropoietin Stimulating Agents Market

A strategic analysis of the Erythropoietin Stimulating Agents Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Erythropoietin Stimulating Agents Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Biocon Limited, Celltrion, Inc., Cipla Limited, Dr. Reddys Laboratories Ltd., F. Hoffmann-La Roche Ltd., Intas Pharmaceuticals Limited, Johnson & Johnson, Kyowa Kirin Co., Ltd., LG Life Sciences Ltd., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Erythropoietin Stimulating Agents Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Darbepoetin Alfa, Epoetin Alfa, Epoetin Beta, Epoetin-Delta, and Epoetin-Omega.
  • Based on Application, market is studied across Anemia, Antiretroviral Treatment, Cancer Chemotherapy, Kidney Disorders, Neural Disease, Oncology Diseases, and Wound Healing.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of HIV, cancer, and ESRD globally
      • 5.1.1.2. Increasing development of synthetic forms of ESRD with enhanced recombinant DNA technology
      • 5.1.1.3. Favorable government initiatives to increase healthcare infrastructures
    • 5.1.2. Restraints
      • 5.1.2.1. High cost EPO drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of novel drugs and cost-efficient biosimilar formulations
      • 5.1.3.2. Ongoing robust research and development activities to develop innovative molecules
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory protocols for drug approval
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Erythropoietin Stimulating Agents Market, by Type

  • 6.1. Introduction
  • 6.2. Darbepoetin Alfa
  • 6.3. Epoetin Alfa
  • 6.4. Epoetin Beta
  • 6.5. Epoetin-Delta
  • 6.6. Epoetin-Omega

7. Erythropoietin Stimulating Agents Market, by Application

  • 7.1. Introduction
  • 7.2. Anemia
  • 7.3. Antiretroviral Treatment
  • 7.4. Cancer Chemotherapy
  • 7.5. Kidney Disorders
  • 7.6. Neural Disease
  • 7.7. Oncology Diseases
  • 7.8. Wound Healing

8. Americas Erythropoietin Stimulating Agents Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Erythropoietin Stimulating Agents Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Erythropoietin Stimulating Agents Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen Inc.
  • 2. Biocon Limited
  • 3. Celltrion, Inc.
  • 4. Cipla Limited
  • 5. Dr. Reddys Laboratories Ltd.
  • 6. F. Hoffmann-La Roche Ltd.
  • 7. Intas Pharmaceuticals Limited
  • 8. Johnson & Johnson
  • 9. Kyowa Kirin Co., Ltd.
  • 10. LG Life Sciences Ltd.
  • 11. Pfizer Inc.
  • 12. Sun Pharmaceutical Industries Ltd.
  • 13. Teva Pharmaceutical Industries Ltd.
  • 14. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. ERYTHROPOIETIN STIMULATING AGENTS MARKET RESEARCH PROCESS
  • FIGURE 2. ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ERYTHROPOIETIN STIMULATING AGENTS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ERYTHROPOIETIN STIMULATING AGENTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ERYTHROPOIETIN STIMULATING AGENTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ERYTHROPOIETIN STIMULATING AGENTS MARKET DYNAMICS
  • TABLE 7. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY DARBEPOETIN ALFA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY EPOETIN ALFA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY EPOETIN BETA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY EPOETIN-DELTA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY EPOETIN-OMEGA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY ANEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY ANTIRETROVIRAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY CANCER CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY KIDNEY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY NEURAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY ONCOLOGY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY WOUND HEALING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 35. ASIA-PACIFIC ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. AUSTRALIA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. AUSTRALIA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. CHINA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. CHINA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. INDIA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. INDIA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. INDONESIA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. INDONESIA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. JAPAN ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. JAPAN ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. MALAYSIA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. MALAYSIA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. PHILIPPINES ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. PHILIPPINES ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. SINGAPORE ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. SINGAPORE ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. SOUTH KOREA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. SOUTH KOREA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. TAIWAN ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. TAIWAN ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. THAILAND ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. THAILAND ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. VIETNAM ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. VIETNAM ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. DENMARK ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. DENMARK ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. EGYPT ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. EGYPT ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. FINLAND ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. FINLAND ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. FRANCE ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. FRANCE ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. GERMANY ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. GERMANY ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. ISRAEL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. ISRAEL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. ITALY ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. ITALY ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. NETHERLANDS ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. NETHERLANDS ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. NIGERIA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. NIGERIA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. NORWAY ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. NORWAY ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. POLAND ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. POLAND ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. QATAR ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. QATAR ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. RUSSIA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. RUSSIA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SAUDI ARABIA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SAUDI ARABIA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH AFRICA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH AFRICA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. SPAIN ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. SPAIN ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. SWEDEN ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. SWEDEN ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. SWITZERLAND ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. SWITZERLAND ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. TURKEY ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. TURKEY ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED ARAB EMIRATES ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED ARAB EMIRATES ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED KINGDOM ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED KINGDOM ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. ERYTHROPOIETIN STIMULATING AGENTS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 108. ERYTHROPOIETIN STIMULATING AGENTS MARKET, FPNV POSITIONING MATRIX, 2023